ArticleFrontiers in immunology2023
High loading-dose of dupilumab resulted in rapid disease control in pediatric patients with atopic dermatitis.
Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 3 syntheses or guidelines pooled it, 11 citations in OpenAlex.
- Efficacy, Safety, Quality of Life, and Adherence of Dupilumab in Pediatric Atopic Dermatitis: A Systematic Review.Clinical drug investigation · 2026Pooled it
- Biomarkers for therapeutic response and adverse outcomes in atopic dermatitis: A systematic review.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Pooled it
- Novel Therapeutic Strategies for Atopic Dermatitis: Biomarker Modulation and Clinical Implications. A Systematic Review.Clinical reviews in allergy & immunology · 2026Pooled it
- Dupilumab efficacy in children aged 6 months to younger than 6 years with moderate-to-severe atopic dermatitis and clinical characteristics of early super-responders.BMC pediatrics · 2026Article
- Immune and environmental predictors of disease severity in atopic dermatitis: a retrospective cohort study.American journal of translational research · 2026Article
- Real-World Efficacy and Safety of Dupilumab Use in Japanese Adult Patients with Atopic Dermatitis: A Single-Center, Retrospective, 104-Week, Observational Study.Diseases (Basel, Switzerland) · 2025Article
- The Association of Inflammatory Indexes Derived from Peripheral Blood Cell Count and Clinical Signs with Response to Treatment with Dupilumab in Pediatric Patients with Moderate-to-Severe Atopic Dermatitis.Journal of inflammation research · 2025Article
- Impact of Overweight on Response to Dupilumab Treatment in Chronic Rhinosinusitis with Nasal Polyps.Nutrients · 2024Article
- Adipokines in atopic dermatitis: the link between obesity and atopic dermatitis.Lipids in health and disease · 2024Review
- Safety of dupilumab in Chinese pediatric patients aged 6 months and older: a prospective real-world study.Frontiers in pediatrics · 2024Article
- A Review of Dupilumab in the Treatment of Atopic Dermatitis in Infants and Children.Drug design, development and therapy · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The real-world experience of dupilumab in Chinese is limited, and the initial loading dose has not yet been deeply explored in patients aged <6 years. Objective: To explore the efficacy and safety of dupilumab in Chinese patients with moderate-to-severe atopic dermatitis and investigate the effect of higher loading dose for disease control in patients aged <6 years. Methods: A total of 155 patients were divided into three groups according to age: <6 years, 6-11 years, and >11 years. Among patients aged <6 years, 37 patients received a high loading dose of 300 mg for body weight <15kg or 600 mg for body weight ≥15kg, and another 37 patients received a standard loading dose of 200 mg for body weight <15kg or 300 mg for body weight ≥15kg. Multiple physicians and patient-reported outcome measures were evaluated at baseline and 2, 4, 6, 8, 12, and 16 weeks after dupilumab treatment. Results: The proportion of patients showing an improvement of ≥75% in the Eczema Area and Severity Index was 68.0% (17/25), 76.9% (10/13), and 62.5% (25/40) in the aged <6, 6-11, and >11 years groups, respectively, at week 16. After increasing the loading dose, 69.6% (16/23) of patients aged <6 years achieved 4-point improvement in Pruritus Numerical Rating Scale at week 2, compared with 23.5% (8/34) of patients receiving standard loading dose ( Conclusions: Dupilumab was effective and well-tolerated in Chinese patients with atopic dermatitis. The increased loading dose helped achieve rapid pruritus control in patients aged <6 years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.